title: [Should drug-induced gynecomastia be monitored?].
authors.forename: X
authors.initials: X
authors.lastname: Nicolas
authors.forename: H
authors.initials: H
authors.lastname: Granier
authors.forename: J L
authors.initials: JL
authors.lastname: Grippari
authors.forename: C
authors.initials: C
authors.lastname: Bergez
authors.forename: J P
authors.initials: JP
authors.lastname: Laborde
authors.forename: F
authors.initials: F
authors.lastname: Talarmin
mesh_terms: D000368:Aged; D000638:Amiodarone / Q000009:adverse effects* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy; D005260:Female; D006177:Gynecomastia / Q000139:chemically induced*; D006801:Humans; D007049:Iatrogenic Disease
chemical_list: D000889:Anti-Arrhythmia Agents; D000638:Amiodarone
vernacular_title: Faut-il surveiller une gynécomastie médicamenteuse?